Drug intelligence / Profile preview

VRC-FLUDNA047-00-VP

Development stage: Phase 1
Lead developer: Vaccine Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Jet Injection

Overview

A DNA vaccine designed to express hemagglutinin (HA) proteins matching the 2008/09 seasonal influenza strains: A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and B/Florida/4/2006. It contains a CMV/R promoter and was developed as part of a prime-boost vaccination strategy against seasonal influenza.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on VRC-FLUDNA047-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-FLUDNA047-00-VP.

Explore the full profile